Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

Recent News and Articles on the Keywords: aortic valve + 92,900 + web  Related to the article below (Last Update: 8/5/2008)

ATS Medical Announces Second Quarter Results MSN Money - ATS 3f(R) Aortic Bioprosthesis: The Company's first generation tissue valve was launched on a targeted basis in several international markets in the first ...ATSI The Money Times Vytorin Didn't Slow Aortic Valve Disease - Study CNNMoney.com - Jul 21, 2008 The study, known as "SEAS," found no significant difference between treatment groups for cardiovascular events associated with aortic valve disease and ... Vytorin didn't help heart valve disease, study reports Houston Chronicle Vytorin Fails to Lower Heart Valve Problems U.S. News & World Report Study finds Vytorin doesn't reduce progression of aortic valve disease Trading Markets (press release) Bloomberg - In-Forum all 924 news articles »  SGP - MRK - OTC:CMTX Atrioventricular Block After Transcatheter Balloon Expandable ... Cardiosource, DC - Jul 30, 2008 Study Question: What is the incidence of atrioventricular (AV) block associated with transcatheter aortic valve replacement (AVR)? ... The Association Between the Timing of Valve Surgery and 6-Month ... Cardiosource all 2 news articles » Study finds Vytorin doesn't reduce progression of aortic valve disease 華富財經, Hong Kong - Jul 21, 2008 In relation to the stock quote service (the "Quote Service") information, the stock price, trade volume and turnover are provided by The Stock Exchange of ... For first time in Israel, heart valves replaced using catheter Jerusalem Post, Israel - Jul 30, 2008 The technique is usually carried out on the mitral valve or the aortic valve. The mitral is located between the upper-left chamber (left auricle) of the ... MedPage Today Simvastatin-Ezetimibe Combination Does Not Slow Progression of ... DG News - Jul 21, 2008 The secondary endpoints were aortic valve disease events and atherosclerotic disease events. Subsidiary outcomes included echocardiographic evidence of ... Results From the SEAS (Simvastatin and Ezetimibe in Aortic ... MarketWatch Vytorin misses primary end point in SEAS study TheHeart.Org Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Cardiosource StreetInsider.com (subscription) all 40 news articles »  SGP - MRK Cholesterol Drugs Linked With Cancer Risk The Epoch Times, NY - Aug 1, 2008 This four-year study assessed the effect of Vytorin (or placebo) in individuals suffering from a narrowing of the aortic valve in the heart (aortic ... ? A gentler method to replace heart valves Hamilton Spectator, Canada - Aug 1, 2008 The new procedure uses a catheter threaded through an artery in the leg, similar to an angioplasty, to replace a damaged aortic valve with a porcine (pig) ... Aortic Valve Disease in Turner Syndrome Cardiosource, DC - Jul 11, 2008 Study Question: What is the prevalence of aortic valve disease in girls and women with Turner syndrome? Methods: A prospective study of 253 individuals with ... Ticker fix spares patient open-heart risk Chicago Sun-Times, United States - Jul 22, 2008 Edward R. Hohmann has an aortic valve replacement that was inserted through the groin to his aorta without any open heart surgery. ...

Percutaneous aortic valve replacement safe, successful in high-risk patients

Catheter technique offers hope to patients turned down for surgery

(May 10, 2007—ORLANDO, FL) -- Catheter techniques are expanding into new territory, successfully aiding in the replacement of narrowed, calcified aortic valves in patients too sick to withstand open-chest surgery. According to a study reported at the 30th Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions (SCAI), May 9–12, 2007, in Orlando, FL, patients who were treated with the CoreValve Revalving System (CoreValve, Irvine, CA) experienced improvements in both the size of the aortic valve and in the severity of heart failure.

To evaluate the CoreValve system, Anita Asgar, M.D., and her colleagues at Montreal Heart Institute recruited 17 elderly patients with a severely narrowed aortic valve, all of whom had been turned down for surgery because of other health problems. In severe narrowing, or stenosis, of the aortic valve, the heart has difficulty pumping blood from the left ventricle to the rest of the body. The result is a back-up of fluid into the lungs and severe shortness of breath with even minimal activity.

Article continues below and (thank you)

With the CoreValve system, aortic valve replacement is performed by threading a special delivery catheter through the femoral artery in the groin and into the aorta in a direction opposite, or retrograde, to the normal flow of blood. Once the catheter is properly positioned in the opening of the aortic valve, it is pulled back to release the CoreValve, a self-expanding stent-like frame with the new tissue valve attached to its core. As it expands, the CoreValve covers the diseased natural valve leaflets.

During the procedure, the patients were placed on a bypass pump for an average of 30–40 minutes to minimize blood flow through the aorta and ease placement of the replacement valve.

All 17 patients survived the procedure. One patient died 5 days later from stroke. Five additional patients died after discharge from the hospital from health problems unrelated to the replacement valve. Follow-up in the 11 survivors showed that the average aortic valve area more than doubled, on average, following the procedure. In addition, the severity of heart failure significantly improved, as gauged by both B-type natriuretic peptide (NT-BNP), a protein produced by the ventricles of the heart during heart failure, and New York Heart Association (NHYA) classification. After the procedure, patients were ranked in NYHA class II, on average, suggesting most were able to engage in a moderate level of activity before becoming short of breath.

About SCAI

Headquartered in Washington, DC, the Society for Cardiovascular Angiography and Interventions is a 3,700-member professional organization representing invasive and interventional cardiologists in 70 nations. SCAI’s mission is to promote excellence in invasive and interventional cardiovascular medicine through physician education and representation, and advancement of quality standards to enhance patient care. SCAI’s annual meeting has become the leading venue for education, discussion, and debate about the latest developments in this dynamic medical specialty.